Rexahn Pharmaceuticals, Inc.
http://www.rexahn.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rexahn Pharmaceuticals, Inc.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Financing Quarterly Statistics, Q2 2022
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Ocuphire Posts Second Phase III Success In Reversing Pupil Dilation
Nyxol is almost set for an NDA filing for reversal of dilation during eye exams/surgery. The reformulation of phentolamine is also being studied in presbyopia, setting up possible competition with AbbVie’s Vuity.
Israel’s Kamada Eyes $40m Sales As Alvotech Alliance Increases
Following on from its initial 2019 alliance, Israel’s Kamada has added a further two biosimilar products to its local distribution agreement with Alvotech. The firm’s CEO discussed its planned foray into the biosimilar space as part of a letter to shareholders.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Site Specific
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- Ocuphire Pharma, Inc.